AQEMIA key facts
as of Oct 2026- Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets.
- AQEMIA is valued at approximately $243.6M as of Oct 2026 (last reported valuation).
- It has raised $69.5M; the latest was Grant ($7.4M) in Apr 2025.
- Notable investors include Bpifrance, La French Tech, Agoranov, Cathay Innovation, Cathay Capital — 12 tracked in total.
- Status: Privately Held (backing).
AQEMIA's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch AQEMIA: the Monday email on marks, rounds and moves
AQEMIA funding rounds
No funding rounds for AQEMIA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AQEMIA
12+Membership and data by Private Market View
AQEMIA valuation
AQEMIA's last reported valuation was $244 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
AQEMIA investors
12 investors are on record for AQEMIA, including Bpifrance, La French Tech, Agoranov and Cathay Innovation.
About AQEMIA
Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's platform combines machine learning and quantum-inspired statistical mechanics algorithms to generate lead-like molecules for a given target, enabling researchers to efficiently and accurately predict the affinity between drug candidates and therapeutic targets.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 84
- Website
- aqemia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.